[Autoimmune encephalitis: psychiatric aspects].

Autoimmune encephalitis is a group of diseases researched by both neurologists and psychiatrists. Despite a large number of studies and practical recommendations, the differential diagnosis and early diagnostics still remains an important issue. The most difficult to diagnose are cases that debut as mental disorders and/or occur without neurological symptoms.

[Autoimmune encephalitis in psychiatric institution (clinical case)].

Currently there is a new concept of «molecular neuropsychiatry» which aim is identification of biomarkers and biological substrates for mental disorders. Autoimmune encephalitis can start with psychiatric symptoms in 60% of cases. In this article we described a clinical case of a patient, 31 years old, with GABAb-associated AE started with acute polymorphic psychosis.

[Social, demographic and clinical characteristics of female patients with schizophrenia and HIV].

Objective: To evaluate social, demographic and clinical characteristics of women with schizophrenia and HIV.

Material And Methods: Medical histories of patients who were in inpatient treatment during 2017 were retrospectively studied. A total of 174 medical histories were analyzed, but the final analysis included 40 HIV-infected patients (main groups) and 48 patients without HIV infection (comparison group).

[The use of long acting antipsychotics in outpatient care].

Objective: To determine the frequency of administration, efficacy and safety of long acting antipsychotics in day-to-day psychiatric practice in outpatient clinics.

Material And Methods: The study included 90 patients with schizophrenia treated with haloperidol decanoate (=18), rispolept consta (=19), clopixol depot (=25), paliperidone palmitate (=25). Symptoms of schizophrenia were assessed with PANSS during 12 months.

[Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease].

Objective: To study the antioxidant profile of blood plasma in patients with paranoid schizophrenia and Alzheimer disease (AD).

Material And Methods: Thirty-three patients with paranoid schizophrenia and 18 patients with AD were included in the study. Patients with schizophrenia were stratified into two subgroups by response to therapy.

[The functional activity of neutrophils in paranoid schizophrenia and Alzheimer's disease].

Objective: To evaluate the radical-producing function of neutrophils in paranoid schizophrenia and Alzheimer's disease.

Material And Methods: The study included 40 patients with paranoid schizophrenia and 22 with Alzheimer's disease. To assess the functional activity of neutrophils, whole blood samples were analyzed using the chemiluminescent method with two-step cell stimulation.

Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia.

Background: Long-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when the most can be done before disease progression associated with poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 12 months.

Methods: This was an international, multicenter, exploratory, retrospective chart review of medical records of adult patients who were newly diagnosed (not more than 1 year before initiation of PP1M treatment) with schizophrenia and who had received continuous treatment with PP1M for ≥12 months in naturalistic clinical settings.

[Impairment of attention and executive functions in patients with paranoid schizophrenia].

To study changes in attention and executive functions during psychopharmacotherapy in patients with paranoid schizophrenia, we have examined 120 patients with a first episode of paranoid schizophrenia treated with typical and atypical neuroleptics. Clinical and statistical analyses have revealed the heterogeneity within treatment groups that allowed to define two subgroups. These subgroups were characterized by a differed disease course (favorable or poor type).